Clinical trials: Denosumab, completed
Non-Small Cell Lung Cancer
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
- Trial name
- NCT01951586
- Testing
- Denosumab, Zoledronic acid, Standard Chemotherapy
- Where
- 74 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Amgen
Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
This phase I trial studies the side effects and best dose of everolimus when given together with anakinra or denosumab in treating participants with cancers that have spread to other places in the body and have come back or…
- Conditions
- Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
- Trial name
- NCT01624766
- Testing
- Anakinra, Denosumab, Everolimus
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- M.D. Anderson Cancer Center
Postmenopausal Osteoporosis
Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients
This study, which was designed as a prospective observational study, was planned to enroll 75 female patients with postmenopausal osteoporosis who had been using bisphosphonates for more than two years and did not respond to…
- Trial name
- NCT04702204
- Testing
- Denosumab 60 MG/ML
- Where
- Turkey (Türkiye)
- Volunteers
- 73 people
- Sponsor
- Nigde Omer Halisdemir University
Osteoporotic Vertebral Compression Fracture
Denosumab and Osteoporotic Vertebral Compression Fracture
This study aimed to investigate the effect of denosumab on bone mineral density(BMD), bone turnover markers(BTMs), functional status, secondary fracture rate, and adverse effects in osteoporotic vertebral compression fracture…
- Trial name
- NCT05058443
- Testing
- Denosumab 60 mg/ml [Prolia]
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shenzhen People's Hospital
Osteoporosis
Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis
The purpose of this study is to study the efficacy of denosumab, a new drug, in the treatment of osteoporosis in patients using bisphosphonates.
- Trial name
- NCT01465568
- Testing
- Denosumab, bisphosphonates
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tuen Mun Hospital
Postmenopausal Women With Osteoporosis
Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis
This study was conducted to assess if there were any clinically meaningful differences in pharmacokinetics (PK), pharmacodynamics (PD), efficacy, safety, or immunogenicity between GP2411 (proposed biosimilar denosumab) and…
- Trial name
- NCT03974100
- Testing
- GP2411, EU-Prolia (EU-authorized Prolia®)
- Where
- 42 sites in United States, Bulgaria and 4 more
- Volunteers
- 527 people
- Sponsor
- Sandoz
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple…
- Trial name
- NCT00330759
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 1,779 people
- Sponsor
- Amgen
Osteoporosis in Postmenopausal Women
Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT)
Primary objective: To compare the bone mineral density (BMD) change under the treatment of denosumab with eldecalcitol or native vitamin D in postmenopausal women with osteoporosis on bone mineral density.
- Trial name
- ESCORT (NCT05884372)
- Testing
- Eldecalcitol, Native Vitamin D, Denosumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xi'an Honghui Hospital
Healthy Male Volunteers
Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male Subjects
Part I of the study： This is a randomised, single-dose, subcutaneous injection, parallel study designed to compare the PK of HLX14 and EU-sourced Prolia® in healthy Chinese adult male subjects, and to assess the safety…
- Trial name
- NCT04534582
- Testing
- HLX14, EU-Prolia®, US-Prolia®
- Where
- China
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Low Bone Mineral Density, Osteopenia
A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density
The purpose of this study is to compare the immunogenicity profiles of denosumab pre-filled syringe (PFS) and vial at 6 months in postmenopausal women with low bone mineral density (BMD).
- Conditions
- Low Bone Mineral Density, Osteopenia, Osteoporosis
- Trial name
- NCT00515463
- Testing
- denosumab
- Volunteers
- 311 people
- Sponsor
- Amgen
Osteoporosis, Osteoporosis Fracture
Post-fracture Medication and Mortality
Osteoporotic fracture is a common public-health problem in the whole world. Although postfracture usage of anti-osteoporosis medications, may reduce mortality, recent results have been inconsistent.
- Conditions
- Osteoporosis, Osteoporosis Fracture, Drug Therapy, Mortality
- Trial name
- NCT05366621
- Testing
- Anti-osteoporosis medications
- Where
- Taiwan
- Volunteers
- 216,155 people, healthy volunteers welcome
- Sponsor
- National Cheng-Kung University Hospital
Osteoporosis
Denosumab Versus Bisphosphonates (Alendronate) in GIOP
A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis
- Trial name
- NCT03005678
- Testing
- Denosumab, Alendronate
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Tuen Mun Hospital
Postmenopausal Osteoporosis, Diabetes Type 2
MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis
The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.
- Trial name
- NCT03472846
- Testing
- Prolia, 60 Mg/mL Subcutaneous Solution, Teriparatide
- Where
- Austria
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Postmenopausal Osteoporosis
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
The purpose of this study is to examine, via iliac crest bone biopsies, the mechanism of combined teriparatide and denosumab on the bone of postmenopausal osteoporotic women after 3 months of treatment.
- Trial name
- NCT04026256
- Testing
- Teriparatide, Denosumab
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Infertility, Male
Denosumab and Male Infertility: a RCT
To determine the significance of systemic RANKL inhibition for male reproduction, conducting a clinical controlled randomized double blinded intervention study on infertile men, to investigating whether Denosumab (Prolia) can…
- Trial name
- NCT03030196
- Testing
- Denosumab
- Where
- Denmark
- Volunteers
- 95 people
- Sponsor
- Martin Blomberg Jensen
Postmenopausal Women Osteoporosis
A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis
This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia® in Chinese postmenopausal women with…
- Trial name
- NCT06804590
- Testing
- 9MW0311, Prolia®
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Gout
Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Bone erosions are a common manifestation and feature of structural damage in severe/chronic tophaceous gout. Management of this destructive and often debilitating gout complication has focused exclusively on urate-lowering…
- Trial name
- NCT02903446
- Testing
- Denosumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
Denosumab Allergy, Zoledronic Acid Allergy
Denosumab vs Zoledronate After Vertebroplasty
Osteoporotic vertebral compression fracture (OVCF) patients had a proportion of secondary fractures after percutaneous vertebroplasty (PVP).
- Trial name
- NCT05598606
- Testing
- Denosumab Injection, Zoledronate
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shenzhen People's Hospital
Postmenopausal
A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture
This is a randomized, double-blind, international multicentre, parallel-controlled phase III clinical study. The study plans to enroll 478 postmenopausal women with osteoporosis at high risk of fracture, whom will be randomized…
- Trial name
- NCT05352516
- Testing
- HLX14, Prolia®
- Where
- 38 sites in China
- Volunteers
- 514 people
- Sponsor
- Shanghai Henlius Biotech
Osteoporosis
A Clinical Trial to Evaluate Efficacy of Once or Twice ZOledronic Acid After Different Duration of denOsumMab Administration in Postmenopausal Women With Osteoporosis (ZOOM Study)
Denosumab(Dmab) is a monoclonal antibody that inhibits the receptor-activator of nuclear factor kappa-B ligand. It improves bone density and reduces fractures by inhibiting osteoclast recruitment and differentiation.
- Trial name
- NCT05361408
- Testing
- Zoledronic acid, once, Zoledronic acid, twice
- Where
- South Korea
- Volunteers
- 114 people
- Sponsor
- Yonsei University